Navigation Links
Acclarent, Inc. Granted Key Patent Covering Balloon Sinuplasty(TM) Technologies
Date:5/3/2009

MENLO PARK, Calif., May 4 /PRNewswire/ -- Acclarent, Inc., the pioneer of Balloon Sinuplasty(TM) technologies for use in the treatment of chronic sinusitis, announced today that the U.S. Patent and Trademark Office awarded U.S. Patent Number 7,500,971, entitled "Devices, Systems and Methods for Treating Disorders of the Ear, Nose and Throat," to the company. This patent and Acclarent's earlier 7,462,175 patent are directed to methods for treating a paranasal sinus ostium, such as the maxillary sinus ostium, either through the nostril or other routes. The patented methods include advancing a balloon through a guide and using the balloon to dilate a paranasal sinus ostium. "In addition to securing protection for this early innovation, we believe this key patent underscores Acclarent's strength in intellectual property and deepens the cornerstone of our patent portfolio for Balloon Sinuplasty(TM)," states Acclarent CEO, Bill Facteau.

With this latest patent, Acclarent now owns or has exclusive rights to nine issued U.S. patents and over 120 pending U.S. and foreign patent applications.

"Acclarent's innovative Balloon Sinuplasty(TM) technology has been used by physicians throughout the world to improve the quality of life for thousands of patients suffering from chronic rhinosinusitis," said Facteau. "Acclarent is committed to continuing its leadership in innovation. This patent protects an important portion of Acclarent's technology assets and further differentiates Acclarent as a leader in the ENT community. The validation by the USPTO of our invention is a significant step in continuing to provide physicians and patients with access to safe and effective minimally invasive technology."

ABOUT ACCLARENT, INC.

Acclarent is a medical technology company dedicated to the development of innovative products providing new technologies to further meet the needs of ENT patients.


'/>"/>
SOURCE Acclarent, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Acclarent, Inc. Closes $26 Million Financing
2. Lilly Granted Preliminary Injunction to Prevent Launch of Generic Raloxifene
3. Hahnemann University Hospital Granted Surgical Fellowship Training Program for Pelvic Floor Disorders
4. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
5. Rib-X Granted Key Antibiotic Patent in China
6. MonoSol Rx Granted U.S. Article of Manufacture Patent
7. Microfluidic Systems (MFSI) is Granted a Microfluidic Cartridge Patent for DNA Separation
8. Skinvisible Patent Granted for Japan
9. Lilly Granted Temporary Restraining Order to Halt Launch of Generic Raloxifene
10. The 2009 Damon Runyon-Rachleff Innovation Award Granted for Pioneering Ideas for Early Detection of Ovarian and Lung Cancers, Bone Marrow Transplant Safety, and Discovery of New Genetic Markers for Cancer
11. Lupin is Granted USFDA Approval for Levetiracetam Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... , ... August 01, 2015 , ... “ reTXT ” ... at the latest and coolest applications on the market for iOS, Android, and Windows. ... shared with viewers allows users to clarify, edit and delete any message including ones ...
(Date:7/31/2015)... Las Vegas, NV (PRWEB) , ... July 31, 2015 , ... Ticket Down is a ... Las Vegas at the MGM Grand Garden Arena. Fans of every genre of music ... On Friday, September 18th, the first day of the festival, the following artists will perform: ...
(Date:7/31/2015)... CA (PRWEB) , ... August 01, 2015 , ... Super Bowl 50 will ... National Football League’s biggest day each year is the Super Bowl. In the two weeks ... takes place from the host venue. The 2016 Super Bowl game will mark the 50th ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently touted by ... predictive health analytics , Jvion continues to disrupt the predictive analytic and ... that targets patient and population level illness to drive prevention and better health ...
(Date:7/31/2015)... ... ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the newest applicator for ... applicator in the United States as an upgrade to the CoolSmooth applicator cleared by ... required a 2 hour treatment time. The new CoolSmooth Pro reduces the treatment ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... of life for patients with chronic rheumatic diseases. ... patient, is// out to improve the way rheumatology ... an hour-long audioconference on April 17, she will ... research, give practical communication tips and share her ...
... nature, in the form of an extract from the bark ... a notorious type of childhood// eye cancer, called retinoblastoma. Retinoblastoma ... about one in 15000 children. ,Usually the cancer ... untreated can be fatal. Dr. Joan O'Brien of the University ...
... Protocol-driven insulin therapy on the medical-surgical wards resulted in ... patients with diabetic foot ulcers. As a result, shorter ... ,“This is the first randomized pilot trial to showcase ... help to improve diabetes control,” Alicia Leung, MD, at ...
... to pay for medical treatment and prescriptions is common ... recovery//, more angina, poorer quality of life and higher ... at Yale School of Medicine. ,The study ... care services or medication were associated with worse patient ...
... diagnosed with aggressive prostate cancer, many men are told that ... best. Often this means patients are told to watch and ... new study has found that either surgical removal of the ... expectancy for these patients when compared with those receiving the ...
... state of Tamilnadu has launched a free nutritional supplement ... Food Programme of the United Nations (UNWFP) would ... scheme called Nutriplus. ,Gian Pietro Bordignon, ... the government of Tamilnadu signed on Friday a memorandum ...
Cached Medicine News:Health News:Destroying Taboos to Improve Patient Care 2Health News:New Research May Pave the Way for Shorter Hospital Stays for Diabetes Patients 2Health News:Due to Cost, Heart Attack Patients Often Avoid Follow-up Care and Medication 2Health News:Surgery, Radiation Treatment Double Life Expectancy for Prostate Cancer Patients 2
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
(Date:7/30/2015)... July 30, 2015 Edwards Lifesciences Corporation (NYSE: ... valves and hemodynamic monitoring, today announced that Robert A. ... "Bob is an ardent champion for innovation in ... to have him on Edwards, board as we pursue our ... chairman and CEO.  "Bob has provided a valuable perspective to ...
(Date:7/30/2015)... July 30, 2015  ResMed Inc. (NYSE: RMD ... 30, 2015.  Revenue for the quarter was $453.1 million, ... June 30, 2014 (a 17 percent increase on a ... with the quarter ended June 30, 2014.  Diluted earnings ... the quarter ended June 30, 2014.  ...
Breaking Medicine Technology:Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... 2011 Researchers presented data demonstrating increased specificity ...  MRI for the detection of breast cancer at ... National Interdisciplinary Breast Center Conference held March 12 ... poster presentation, titled Pre-Surgical Detection of Malignancies ...
... Varian Medical Systems (NYSE: VAR ) announced ... fiscal year 2011 following the close of regular trading on ... by a teleconference available to all interested parties at 2:00 ... conference call webcast will be available on the company website ...
Cached Medicine Technology:Researchers Present Key Findings Comparing PEM to MRI for Identification of Contralateral Breast Cancer at the National Consortium of Breast Centers (NCBC) Conference 2Varian Medical Systems Schedules Second Quarter FY2011 News Release and Conference Call 2
... AFX Lens is a direct ... in an air-filled eye. In ... a primary air-fluid exchange vitrectomy ... sutureless design make it well ...
... Prism is designed for ... are recommended for tractional ... etc.) and Rhegmatogenus retinal ... used for panretinal photocoagulation ...
... The 30° Prism ... fundus pathologies and are ... detachments (PDR, BRVO etc.) ... They can be used ...
The Chalam Mid Field lens can be used for air/gas exchange and has a bi-concave design to provide the widest field available in a direct image surgical lens. This lens was developed with K.V. Chalam,...
Medicine Products: